

WeirFoulds represents Antibie Therapeutics Inc. in completion of \$5.75-million bought deal public offering

March 11, 2019

On February 27, 2019, [Antibie Therapeutics Inc. \(TSXV: ATE, OTCQB: ATBPF\)](#) announced that it closed its previously announced [bought deal public offering](#) of 23,000,000 units of the Company at a price of \$0.25 per Unit for aggregate gross proceeds of \$5,750,000. The team from WeirFoulds that represented Antibie in the deal included Robert Eberschlag, David Knight, Ryan Morris, Daniel Tessaro and Ann Lattanzio.

Each Unit was comprised of one common share of the Company and one-half of one common share purchase warrant. The net proceeds of the Offering will be used to fund research and development activities, including but not limited to, ATB-346's clinical development, regulatory consulting fees, working capital needs and other general corporate purposes. Antibie develops safer medicines for pain and inflammation. Antibie's technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine.

WeirFoulds is proud to have assisted Antibie Therapeutics in the closing of this significant deal.

To learn more about our Corporate Law Practice Group or to contact one of our lawyers, visit our [Corporate & Commercial overview page](#).

WeirFoulds^{LLP}

www.weirfoulds.com

Toronto Office

4100 – 66 Wellington Street West
PO Box 35, TD Bank Tower
Toronto, ON M5K 1B7

Tel: 416.365.1110
Fax: 416.365.1876

Oakville Office

1320 Cornwall Rd., Suite 201
Oakville, ON L6J 7W5

Tel: 416.365.1110
Fax: 905.829.2035